U.K.’s cost-effectiveness agency: Alzheimer’s drug does not provide good value

Taking stock of the drug industry, from the lab to the medicine chest

October 23, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | U.K.'s cost-effectiveness agency says Alzheimer's drug donanemab does not provide good value The Eli Lilly drug will not be made available in the NHS unless the agency, NICE, finds that the medicine's benefits justify its costs. By Andrew Joseph STAT+ | Novo asks FDA to bar compounders from making Ozempic copies The agency posted documents from the drugmaker requesting semaglutide be placed on the FDA's 'Demonstrable Difficulties for Compounding Lists' By Elaine Chen STAT+ | Q&A: Mark Cuban explains his beef with traditional PBMs — and why he thinks disruption is inevitable The billionaire best known for his past role on the TV show "Shark Tank" is seeking to disrupt the system around prescription drug sales in the U.S. By STAT Staff Kayana Szymczak for STAT More state Medicaid programs consider covering GLP-1 drugs Most state Medicaid programs don't cover weight loss drugs for obesity, but that could soon change, per KFF report. By Tara Bannow STAT+ | What's on the docket for Congress post-election: Chinese biotech, Medicare payments, ACA subsidies From the BIOSECURE Act to a telehealth extension to Medicare payments, key health policy issues could see breakthroughs in the lame duck session of Congress. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser